This week at the World Vaccines Congress in Spain, Sanofi Pasteur announced that in collaboration with the University of Georgia it has developed a candidate flu vaccine through genetic sequencing of many flu viruses. The vaccine, dubbed Cobra, is designed to protect against multiple strains over several years using common sequences the strains share.
Australia's CSL, which completed its acquisition of Novartis' flu vaccines business this year, has launched a AU$1 million share buyback.
As part of its responsibility to prepare for public health threats, the U.S. Department of Health and Human Services' BARDA unit is seeking more effective influenza vaccines to incorporate into its pandemic strategy. Now, it's funding two projects it hopes will help the state of affairs.
Just in time for flu season, AstraZeneca granted Daiichi Sankyo an exclusive license to market its FluMist Quadrivalent in Japan. The live attenuated vaccine, delivered nasally, went through Phase III trials in Japanese children, and a regulatory submission is being prepared for Japan.
A day after two high-profile organizations announced successful animal results for their own universal flu vaccine, Madison, WI-based FluGen announced a $12 million Series A round to fund the development of its candidate in the race.
The NIAID may have posted 94% efficacy in mice for its investigational "universal" flu vaccine, but The Scripps Research Institute and partner Johnson & Johnson are hot on its heels.
Flu vaccines have grown into a multibillion-dollar business, but researchers at the Ohio State University have published findings that could one day transform the field and put a damper on those figures.
Novavax is making waves in the influenza space, reporting positive Phase II results for its quadrivalent seasonal flu vaccine on Thursday.
A vaccine against a wide range of flu viruses has long eluded scientists, but NIAID researchers have discovered what could be the foundation of a 'universal' flu vaccine.
Protein Sciences released data showing that Flublok Quadrivalent--its follow-up to the FDA-approved trivalent Flublok--outperformed the traditional egg-based quadrivalent vaccine.